专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110086070A1 Orally disintegrating compositions of rhein or diacerein 审中-公开
标题翻译：口服崩解大黄酸或双醋瑞因组合物
公开(公告)号：US20110086070A1
公开(公告)日：2011-04-14
申请号：US12934122
申请日：2008-09-26
申请人： Munish Talwar , Rahul Dabre , Ritesh Kapoor , Himanshu Verma , Nitin Jain , Girish Kumar Jain
发明人： Munish Talwar , Rahul Dabre , Ritesh Kapoor , Himanshu Verma , Nitin Jain , Girish Kumar Jain
IPC分类号： A61K31/235 , A61K31/192 , A61K9/00
CPC分类号： A61K9/0056 , A61K9/2054 , A61K9/7007 , A61K31/192 , A61K31/235
摘要： The invention relates to orally disintegrating pharmaceutical compositions comprising rhein or diacerein, or salts or esters or prodrugs thereof, and processes for preparing such compositions.
摘要翻译：本发明涉及包含大黄酸或双醋瑞因或其盐或酯或前药的口服崩解药物组合物，以及制备该组合物的方法。

2. 发明申请

US20090111788A1 ANTIBIOTIC COMPOSITIONS OF MODIFIED RELEASE AND PROCESS OF PRODUCTION THEREOF 审中-公开
标题翻译：改性释放物的抗生素组合物及其生产方法
公开(公告)号：US20090111788A1
公开(公告)日：2009-04-30
申请号：US12294353
申请日：2007-03-07
申请人： Rajesh Jain , Kour Chand Jindal , Munish Talwar
发明人： Rajesh Jain , Kour Chand Jindal , Munish Talwar
IPC分类号： A61K31/43 , A61K31/431 , A61K31/545 , A61K31/426 , A61K31/5383 , A61P11/00 , A61P31/04
CPC分类号： A61K9/5026 , A61K9/284 , A61K9/286 , A61K9/2866 , A61K9/4866 , A61K9/4891 , A61K9/5047 , A61K31/424 , A61K31/43
摘要： Novel modified release pharmaceutical compositions wherein the composition comprises at least one antibiotic(s) preferably amoxicillin or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof either alone or in combination with other antibiotic(s) as active ingredient, with at least one release modifying agent(s) for controlling the release of the beta lactam antibiotic optionally with one or more other pharmaceutically acceptable excipient(s) is provided, wherein the dosage form provides a release of not more than about 60% of the antibiotic in about 30 minutes and not less than about 70% of the antibiotic after 8 hours when subjected to in vitro dissolution study or when tested in vivo. Further, the compositions of the present invention which when tested in a group of healthy humans provide a mean peak plasma concentration (Cmax) after at least about 0.5 hour of administration of the dosage form. The present invention also provides process of preparing such dosage form and methods of using such dosage form.
摘要翻译：新型改性释放药物组合物，其中组合物单独或与其它抗生素组合包含至少一种抗生素，优选阿莫西林或其药学上可接受的盐，酯，多晶型物，异构体，前药，溶剂合物，水合物或衍生物，作为活性成分，提供了至少一种用于控制任选与一种或多种其它药学上可接受的赋形剂释放β-内酰胺抗生素的释放调节剂，其中该剂型提供不超过约在进行体外溶出研究或体内测试后8小时后，约30分钟内有60％的抗生素和不少于约70％的抗生素。此外，当在一组健康人中测试时，本发明的组合物在施用剂型至少约0.5小时后提供平均峰值血浆浓度（C max）。本发明还提供了制备这种剂型的方法和使用这种剂型的方法。

3. 发明申请

US20070128276A1 Controlled release compositions comprising nimesulide 审中-公开
标题翻译：含有尼美舒利的控制释放组合物
公开(公告)号：US20070128276A1
公开(公告)日：2007-06-07
申请号：US11545718
申请日：2006-10-10
申请人： Rajesh Jain , Kour Jindal , Munish Talwar
发明人： Rajesh Jain , Kour Jindal , Munish Talwar
IPC分类号： A61K9/22 , A61K31/165
CPC分类号： A61K9/4891 , A61K9/0004 , A61K9/2054 , A61K9/209 , A61K9/2853 , A61K9/2866 , A61K9/5078 , A61K9/5084 , A61K31/18
摘要： A controlled release composition comprising nimesulide as an active agent formulated as a gastroretentive system, preferably as a solid oral dosage form is provided, wherein the residence time of the active agent is increased in the stomach, duodenum, jejunum or ileum. The present invention also provides process of preparing such dosage form and methods of using such dosage form compositions. The dosage form compositions are preferably administered once-a-day or twice-a-day and are particularly very useful in the prophylaxis or treatment of NSAID indicated disorder(s) such as acute painful conditions like post-operative trauma, pain associated with cancer, sports injuries, migraine headache and the like, or chronic diseases such as arthritis and the like.
摘要翻译：提供了包含尼美舒利作为配制为胃滞留系统的活性剂，优选为固体口服剂型的控释组合物，其中活性剂在胃，十二指肠，空肠或回肠中的停留时间增加。本发明还提供了制备这种剂型的方法和使用这种剂型组合物的方法。剂型组合物优选每天一次或每天两次施用，并且特别非常有用于预防或治疗NSAID指示的病症，例如急性疼痛病症如手术后创伤，与癌症相关的疼痛，运动损伤，偏头痛等，或诸如关节炎等慢性疾病。

4. 发明授权

US08999381B2 Self-emulsifying pharmaceutical compositions of rhein or diacerein 有权
公开(公告)号：US08999381B2
公开(公告)日：2015-04-07
申请号：US12680335
申请日：2008-09-27
申请人： Premchand Nakhat , Prashant Mandaogade , Girish Kumar Jain , Munish Talwar
发明人： Premchand Nakhat , Prashant Mandaogade , Girish Kumar Jain , Munish Talwar
IPC分类号： A61K9/14 , A61K9/48 , A61K9/107 , A61K31/222 , A61K47/44
CPC分类号： A61K31/235 , A61K9/1075 , A61K9/4825 , A61K9/4858 , A61K31/222 , A61K47/44
摘要： The invention relates to self emulsifying drug delivery system based compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50®. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools effects as compared to Art 50®. The invention also relates to methods for preparing such compositions.

5. 发明授权

US08709485B2 Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability 失效
公开(公告)号：US08709485B2
公开(公告)日：2014-04-29
申请号：US12865745
申请日：2009-02-06
申请人： Munish Talwar , Ritesh Kapoor , Manoj Mashalkar , Girish Kumar Jain
发明人： Munish Talwar , Ritesh Kapoor , Manoj Mashalkar , Girish Kumar Jain
IPC分类号： A61K31/277 , A61K9/14 , A61P25/16
CPC分类号： A61K9/14 , A61K9/145 , A61K9/1635 , A61K9/1652 , A61K9/2054 , A61K9/2077 , A61K31/195 , A61K31/198 , A61K31/275 , A61K31/277
摘要： The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapone, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalevo200®. The invention also relates to processes for making such compositions.

6. 发明申请

US20120231051A1 SINGLE UNIT ORAL DOSE PHARMACEUTICAL COMPOSITION COMPRISING LEVODOPA, CARBIDOPA AND ENTACAPONE OR SALTS THEREOF 审中-公开
标题翻译：单一单位口服药物组合物，包含左旋多巴，卡比多巴和他奈酮或其盐
公开(公告)号：US20120231051A1
公开(公告)日：2012-09-13
申请号：US13482258
申请日：2012-05-29
申请人： Yatendra Kumar GUPTA , Girish Kumar Jain , Munish Talwar , Manoj Mashalkar
发明人： Yatendra Kumar GUPTA , Girish Kumar Jain , Munish Talwar , Manoj Mashalkar
IPC分类号： A61K31/195 , A61P25/16 , A61K9/24 , A61K9/00 , A61K9/52
CPC分类号： A61K45/06 , A61K9/2059 , A61K9/209 , A61K31/198 , A61K31/277 , A61K2300/00
摘要： There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.
摘要翻译：提供单一口服剂量的单一药物组合物，其包含a）左旋多巴或其盐，其以延长释放形式约50mg至约300mg，b）卡比多巴或其盐在约10mg至约100mg的延长释放中，c）恩他卡朋或其盐以约100mg至约1000mg的速释形式，任选地与其它药学上可接受的赋形剂。本发明还涉及这种组合物的制备方法。

7. 发明申请

US20110091558A1 Pharmaceutical Compositions of Entacapone, Levodopa and Carbidopa with Improved Bioavailability 失效
标题翻译：恩他卡朋，左旋多巴和卡比多巴的药物组合物具有改善的生物利用度
公开(公告)号：US20110091558A1
公开(公告)日：2011-04-21
申请号：US12865745
申请日：2009-02-06
申请人： Munish Talwar , Ritesh Kapoor , Manoj Mashalkar , Girish Kumar Jain
发明人： Munish Talwar , Ritesh Kapoor , Manoj Mashalkar , Girish Kumar Jain
IPC分类号： A61K31/277 , A61K9/14 , A61P25/16
CPC分类号： A61K9/14 , A61K9/145 , A61K9/1635 , A61K9/1652 , A61K9/2054 , A61K9/2077 , A61K31/195 , A61K31/198 , A61K31/275 , A61K31/277
摘要： The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapon, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalcvo200®. The invention also relates to processes for making such compositions.
摘要翻译：本发明涉及包含entacapon，左旋多巴和卡比多巴或其盐与一种或多种糖醇的组合的单一口服剂量药物组合物，其中恩他卡朋与一种或多种糖醇共粉碎。本发明的组合物显示出以商品名Stalcvo 200销售的市售的恩他卡朋，左旋多巴和卡比多巴组合制剂的生物等效性。本发明还涉及制备这种组合物的方法。

8. 发明申请

US20110052681A1 Pharmaceutical compositions of entacapone co-micronized with sugar alcohols 有权
标题翻译：恩他卡朋的药物组合物与糖醇共粉碎
公开(公告)号：US20110052681A1
公开(公告)日：2011-03-03
申请号：US12865783
申请日：2009-02-06
申请人： Ritesh Kapoor , Sanjay Mate , Munish Talwar , Girish Kumar Jain
发明人： Ritesh Kapoor , Sanjay Mate , Munish Talwar , Girish Kumar Jain
IPC分类号： A61K9/48 , A61K31/277 , A61K9/14 , A61P25/16
CPC分类号： A61K9/145 , A61K9/1635 , A61K9/2018 , A61K9/2027 , A61K31/275
摘要： The present invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof along with one or more sugar alcohols; wherein the entacapone is co-micronized with one or more sugar alcohols. The invention also relates to processes of making such compositions.
摘要翻译：本发明涉及包含恩他卡朋或其药学上可接受的盐以及一种或多种糖醇的药物组合物; 其中恩他卡朋与一种或多种糖醇共粉碎。本发明还涉及制备这种组合物的方法。

9. 发明申请

US20100303902A1 SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN 审中-公开
标题翻译：瑞芬或二辛胆碱的自我诊断药物组合物
公开(公告)号：US20100303902A1
公开(公告)日：2010-12-02
申请号：US12680335
申请日：2008-09-27
申请人： Premchand Nakhat , Prashant Mandaogade , Girish Kumar Jain , Munish Talwar
发明人： Premchand Nakhat , Prashant Mandaogade , Girish Kumar Jain , Munish Talwar
IPC分类号： A61K9/48 , A61K31/194 , A61K31/225 , A61P1/10
CPC分类号： A61K31/235 , A61K9/1075 , A61K9/4825 , A61K9/4858 , A61K31/222 , A61K47/44
摘要： The invention relates to self emulsifying drug delivery system based compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50®. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools effects as compared to Art 50®. The invention also relates to methods for preparing such compositions.
摘要翻译：本发明涉及基于大黄酸或双醋瑞因或其盐或酯或前药的基于自乳化药物递送系统的组合物，其与以商品名Art 50销售的50mg双醋瑞因制剂是生物等效的。组合物在进食和禁食状态下表现出不变性。与Art 50相比，组合物还导致副作用显着降低，例如软粪便效应。本发明还涉及制备这种组合物的方法。

10. 发明授权

US08758779B2 Pharmaceutical composition of duloxetine 失效
标题翻译：度洛西汀的药物组成
公开(公告)号：US08758779B2
公开(公告)日：2014-06-24
申请号：US13377968
申请日：2010-06-24
申请人： Sanjay Mate , Ritesh Kapoor , Inderjeetsingh Huda , Kasturi Roy , Munish Talwar , Girish Kumar Jain
发明人： Sanjay Mate , Ritesh Kapoor , Inderjeetsingh Huda , Kasturi Roy , Munish Talwar , Girish Kumar Jain
IPC分类号： A61K9/28 , A61K9/16 , A61K9/14 , A61K31/381 , A61K9/00
CPC分类号： A61K9/28 , A61K9/0095 , A61K9/146 , A61K9/1635 , A61K9/1652 , A61K31/381
摘要： The invention relates to a taste masked pharmaceutical composition comprising duloxetine or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions. The invention further discloses an inclusion complex comprising duloxetine or pharmaceutically acceptable salts thereof with one or more cyclodextrin or derivatives thereof.
摘要翻译：本发明涉及包含度洛西汀或其药学上可接受的盐的掩味药物组合物。本发明还涉及制备这种组合物的方法。本发明还公开了包含度洛西汀或其药学上可接受的盐与一种或多种环糊精或其衍生物的包合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式